Oct 2- Eli Lilly and Co said it would discontinue the development of its lupus drug as the treatment was not found to be effective enough in two late-stage trials. The decision will result in a charge of about 4- 5 cents per share in the third quarter, the company said. Eli Lilly said the decision was not because of any safety concerns.» Read More
Shares of Merrimack Pharmaceuticals Inc. jumped Wednesday after the drugmaker said it could receive more than $900 million through a collaboration with Baxter International Inc. over its potential pancreatic cancer treatment.
EL PASO, Texas— An official at a Texas hospital where a nurse assistant potentially exposed more than 750 infants to tuberculosis said Tuesday that her symptoms were discovered in July but that more than a month passed before she was tested for the infectious lung disease.
NEW YORK— Acorda Therapeutics Inc. plans to buy privately-held Civitas Therapeutics for $525 million in cash as the drugmaker seeks to expand into treatments for Parkinson's disease. Acorda, based in Ardsley, New York, makes drugs for patients with multiple sclerosis, spasticity and those who are experiencing pain after a shingles infection.
ALBUQUERQUE, N.M.— A New Mexico company that markets diagnostic tests for lupus and other autoimmune rheumatoid diseases has filed for an initial public offering. The Albuquerque Journal reports that Exagen Diagnostics Inc. recently filed its registration statement with the U.S. Securities and Exchange Commission.
CHICAGO, Sept 24- U.S. hospitals may be unprepared to safely dispose of the infectious waste generated by any Ebola virus disease patient to arrive unannounced in the country, potentially putting the wider community at risk, biosafety experts said.
Margaret Hamburg, who has led the agency since 2009. The FDA has been under fire from public health advocates, politicians and law enforcement officials since last October, when it approved a powerful new painkiller called Zohydro against the recommendation of its own medical advisers.
LONDON, Sept 23- West African nations hit by the Ebola virus epidemic will need international help to rebuild for years to come and it is time for mining companies and business to get involved, the head of the African Development Bank said on Tuesday.
CNBC's Meg Tirell reports the latest projections on the Ebola virus.
The world's attention may have shifted to U.S. airstrikes on Syria, but West Africa continues to be ravaged by the worst outbreak of Ebola.
Sept 23- Between 550,000 and 1.4 million people in West Africa could be infected with the Ebola virus by January 20, 2015, according to a report issued on Tuesday by the U.S. Centers for Disease Control and Prevention.
Sept 22- Canadian drugmaker Tekmira Pharmaceuticals Corp said on Monday that U.S. and Canadian regulators have authorized the use of its Ebola treatment in patients who have confirmed or suspected infections from the deadly virus.
LONDON, Sept 19- The Ebola virus raging through West Africa is mutating rapidly as it tears a deadly path through cities, towns and villages, but the genetic changes are for now not giving it the ability to spread more easily.
The drug, developed by Vivus Inc, is marketed in the United States and Canada by Auxilium Pharmaceuticals Inc. Vivus' stock was up about 13 percent at $4.40 in afternoon trading.
The drug was developed by Auxilium Pharmaceuticals Inc and Vivus Inc.. Vivus owns the worldwide development and commercial rights to Stendra for use in sexual dysfunction, with the exception of certain Asian countries in the Pacific Rim.
PARIS, Sept 18- French cancer immunotherapy specialist OSE Pharma has registered with market regulator AMF for an initial public offering aimed at financing late-stage trials of its Texopi drug for the most common form of lung cancer, the company said on Thursday.
Sept 18- An erectile dysfunction drug that reduces by half the time patients need to take the pill before sexual activity has been approved by the U.S. Food and Drug Administration.
Sept 17- Testosterone replacement therapies should be reserved for men with specific medical conditions that impair function of the testicles, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The FDA is not obliged to follow the advice of its advisory panels but typically does so.
Sept 17- Gilead Sciences Inc said its experimental drug did not significantly improve how long patients with a type of pancreatic cancer lived without the disease worsening. Separately, the biotechnology company also licensed Sovaldi to seven India- based drugmakers that will sell far cheaper versions of the drug in 91 developing nations.
CNBC's Meg Tirrell runs down today's top health care headlines, including a major move by President Obama to fight the Ebola virus and the latest on Enterovirus D68.
Sept 15- Merck& Co said it will seek U.S. approval next year for its long-delayed experimental osteoporosis drug, odanacatib, after it proved effective in a late-stage trial but was associated with rare thigh-bone fractures seen with standard treatments.